9II.F BIOVICA INTL. SK-07
- Market cap
- EUR 7.47M
- P/E
- -
- P/B
- 1.16x
- ROE
- -121.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is 9II.F undervalued?
Graham numberThe Graham number of BIOVICA INTL. SK-07 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOVICA INTL. SK-07 fundamental analysis
No fundamental analysis for BIOVICA INTL. SK-07 yet.
BIOVICA INTL. SK-07 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOVICA INTL. SK-07
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is hea…
Full company profileBIOVICA INTL. SK-07 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOVICA INTL. SK-07 annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.05M | 3.38M | 7.29M | 8.62M | 13.4M | 16.2M |
| Gross Profit | 4.67M | 4.62M | 6.88M | 8.09M | 13.3M | 13.8M |
| Operating Income | -61.3M | -111M | -128M | -88.1M | -70.6M | -81.8M |
| EBITDA | - | -102M | -114M | -76.9M | -60.8M | -74.0M |
| Net Income | -60.0M | -110M | -125M | -87.6M | -69.9M | -80.6M |
| EPS | -1.92 | -2.23 | -1.37 | -0.83 | -0.24 | -0.28 |
| Balance Sheet | ||||||
| Total Assets | 152M | 172M | 131M | 64.9M | 108M | 90.1M |
| Total Liabilities | 27.5M | 33.7M | 34.8M | 21.7M | 21.4M | 23.5M |
| Shareholders' Equity | 124M | 139M | 96.6M | 43.2M | 86.3M | 66.6M |
| Cash & Short-term Investments | 89.8M | 114M | 79.4M | 24.4M | 70.4M | 51.6M |
| Cash Flow | ||||||
| Operating Cash Flow | -52.1M | -94.6M | -115M | -85.4M | -62.8M | -64.4M |
| Capital Expenditure | 3.40M | 2.78M | 146K | 287K | 474K | 7.98M |
| Free Cash Flow | -55.5M | -97.4M | -115M | -85.7M | -63.3M | -72.4M |
| Ratios | ||||||
| ROE | -48.4% | -79.7% | -129.2% | -202.8% | -80.9% | -121.1% |
| ROA | -39.6% | -64.1% | -95.0% | -134.9% | -64.8% | -89.5% |
| Net Profit Margin | -2,934.1% | -3,265.1% | -1,712.2% | -1,016.5% | -522.1% | -498.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOVICA INTL. SK-07 dividends
BIOVICA INTL. SK-07 has not paid dividends in the last 5 fiscal years.
Who owns BIOVICA INTL. SK-07
- Insiders 42.43%
- Institutions 18.81%
- Public & others 38.76%
- Shares outstanding 375M
- Free float 167M
BIOVICA INTL. SK-07 company profile
- Company name
- BIOVICA INTL. SK-07
- Ticker
- 9II.F
- ISIN
- SE0008613731
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- April
- Address
- Dag Hammarskjölds väg 54B, Uppsala, Sweden, 752 37
- Phone
- 46 1 84 44 48 30
- Website
- biovica.com
About BIOVICA INTL. SK-07
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
BIOVICA INTL. SK-07 management
4- Mr. Theis KiplingChief Executive Officer · born 1982
- Ms. Maria EkdahlChief Financial Officer · born 1973
- Ms. Hanna RitzénSenior VP of Global Marketing & Business Development · born 1979
- Mr. Henrik Winther D.V.M., Ph.D.Head & Senior VP of Pharma Services · born 1966